Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albumin human (Primary) ; Immune globulin (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms AMBAR
  • Sponsors Grifols

    • Most Recent Events

    • 20 Jul 2023 Results (n=296) assessing PE-Alb differential effects on metabolites between ApoE4 carriers and non-carriers presented at the Alzheimer's Association International Conference 2023
    • 01 Nov 2022 Results to detect structural and functional brain changes (n = 198) in Alzheimer's disease patients treated with therapeutic plasma exchange (PE) with albumin replacement, published in the European Journal of Nuclear Medicine and Molecular Imaging.
    • 04 Aug 2022 Results assessing plasma exchange with albumin replacement effects on lipidomics across the AMBAR study, presented at the Alzheimer's Association International Conference 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top